OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
RMD
ResMed Inc.
RMD has the edge over OSCR overall, supported by stronger valuation and lower modeled downside.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
RMD's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over RMD in the historical PE scenario, which offers more potential upside but is not a forecast.
RMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $239 | — |
| Current | 22x | $239 | — |
| Cheap | 26x | $280 | +17% |
| Fair | 37x | $410 | +71% |
| Expensive | 54x | $595 | +149% |
Historical ranges are pointers, not guarantees.
RMD's PE is in its cheap range at 22x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over RMD on the outlook, with more favorable revenue expectations.
RMD Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect RMD's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
RMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $12.30 | +12% |
| Q3 2026 | $10.98 | +12% |
| Q2 2026 | $10.43 | +9.7% |
| Q1 2026 | $10.37 | +17% |
| Q4 2025 | $10.11 | +20% |
| Q3 2025 | $9.77 | +30% |
| Q2 2025 | $9.51 | +37% |
| Q1 2025 | $8.90 | +37% |
| Q4 2024 | $8.46 | +40% |
RMD has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RMD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
RMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +5.9% |
| Q2 2026 | $1.5B | +8.6% |
| Q1 2026 | $1.4B | +11% |
| Q4 2025 | $1.4B | +11% |
| Q3 2025 | $1.3B | +9.1% |
| Q2 2025 | $1.3B | +10% |
| Q1 2025 | $1.3B | +7.9% |
| Q4 2024 | $1.3B | +10% |
RMD's revenue has grown year over year for 22 quarters in a row: $1.4B last quarter, up 5.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.4 points |
| Q2 2026 | 31% | -3.1 points |
| Q1 2026 | 35% | +1.9 points |
| Q4 2025 | 35% | +2 points |
| Q3 2025 | 33% | +1.8 points |
| Q2 2025 | 34% | +2.5 points |
| Q1 2025 | 33% | +1.7 points |
| Q4 2024 | 33% | +8.9 points |
RMD has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over RMD on cash flow, with more consistent year-over-year improvement.
RMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $373.7M | -9.8% |
| Q2 2026 | $403.5M | -21% |
| Q1 2026 | $520.5M | -6.7% |
| Q4 2025 | $311.2M | +8.1% |
| Q3 2025 | $414.4M | +35% |
| Q2 2025 | $508.2M | +22% |
| Q1 2025 | $557.9M | +46% |
| Q4 2024 | $288M | +15% |
RMD generated $1.6B in free cash flow over the past year, down 9% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.8% | -2.6M shares |
| 1 year | -2.4% | -3.5M shares |
| 3 years | -2.8% | -4.1M shares |
| 5 years | -2.3% | -3.4M shares |
| Available history | -1.5% | -2.2M shares |
RMD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $936.4M |
| Q2 2026 | $200M |
| Q1 2026 | $175M |
| Q4 2025 | $175M |
| Q3 2025 | $150M |
| Q2 2025 | $100M |
| Q1 2025 | $75M |
| Q4 2024 | $75M |
RMD spent $1.5B buying back its own shares over the past year, about four times what it spent the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over RMD on leverage, with a lower net debt burden relative to earnings.
RMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.5x | Net Cash |
| Q4 2025 | -0.4x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | 0.1x | Very low |
RMD has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.7 | Neutral |
| Stochastic | 60.7 | Neutral |
RMD's weekly RSI is 56 (neutral) and its Stochastic is 61 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over RMD on valuation relative to its sector.
RMD PE vs Healthcare Sector
| Metric | RMD | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 26x | 16% below |
| PE % | 6 | 29 | 23 pts below |
RMD is trading at 22x earnings, a 16% discount to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
RMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $233.4 | 2.4% above |
| 20 week MA | $223.3 | 7% above |
| 50 week MA | $227.8 | 4.8% above |
| 100 week MA | $238.7 | 0.1% above |
| 200 week MA | $220.5 | 8.3% above |
RMD is in an uptrend: it's above all five of its weekly moving averages, and 8.3% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RMD on returns for 2026, with the stronger performance.
RMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $156.2 | $212.4 | +36% |
| 2021 | $212.4 | $258.8 | +22% |
| 2022 | $258.8 | $208.3 | -20% |
| 2023 | $208.3 | $172.0 | -17% |
| 2024 | $172.0 | $233.2 | +36% |
| 2025 | $233.2 | $244.8 | +5% |
| 2026 YTD | $244.8 | $238.9 | -2.4% |
RMD has finished higher in four of the last six years. It's down 2.4% so far in 2026.